23 results about "Anti integrin" patented technology

In some embodiments, the invention provides a method for identifying an agent beneficial to treat a patient with inflammatory bowel disease comprising: a) determining a status of an intestinal barrier in the patient; and b) categorizing the status as severe dysfunction or moderate dysfunction, wherein a patient categorized as having severe dysfunction is identified as a patient who will benefit from treatment with an agent selected from the group consisting of an anti-TNF agent and / or an anti-IL-12 / 23 agent, and a patient categorized as having moderate dysfunction is identified as a patient who will benefit from treatment with an anti-integrin agent, an anti-janus kinase agent, and / or and a sphingosine-1-phosphate receptor agonist agent.

The integrin family of cell adhesion molecules has emerged as key mediators of tissue fibrosis. A pharmacological inhibitor of multiple integrin subtypes is required to produce meaningful effects on delaying or inhibiting the progression of fibrosis. Monoclonal antibodies recognizing multiple integrins with potent neutralizing activity and having human and mouse cross-reactivity are described. In particular, monoclonal antibodies that bind human αvβ1, αvβ3, αvβ5, αvβ36, αvβ38, and α5β1 integrins and mouse αvβ1, αvβ3, αvβ5, αvβ6, and αvβ8 integrins are described.

Provided is a novel pharmaceutical composition for treating or preventing an aging-related disease by utilizing selective removal of a senescent cell. A pharmaceutical composition comprising an anti-integrin α11 (ITGA11) antibody as an active ingredient is administered to a subject.

The present invention addresses the problem of providing a novel anti-integrin α8β1 antibody, and provides an anti-integrin α8β1 antibody including the following heavy chain and light chain: (i) a heavy chain which includes a heavy-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 1, a heavy-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 2, and a heavy-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 3; and (ii) a light chain which includes a light-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 4, a light-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 5, and a light-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 6.

Provided herein are anti-alpha v beta 8 antibodies, or antigen binding portions thereof, and methods of making and using the same. Further provided herein are methods of treating cancer with anti-[ alpha] v [beta] 8 and PD-1 axis antagonists.

This invention proposes a new class of compounds that effectively antagonize integrin α4β7, which are compounds represented by formula (Y), or stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs of compounds represented by formula (Y):

The present disclosure provides antibodies or antigen-binding fragments thereof that bind to alpha5 integrin (e.g., human alpha5 integrin), and uses thereof. In certain embodiments, the disclosed antibodies are humanized antibodies.

Provided are a compound that effectively antagonizes integrin α4β7, which is a compound represented by formula (Y), or a stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug of the compound represented by formula (Y).

Anti-alpha4beta7 integrin antibody liquid formulations are described that have a high concentration of antibody, e.g., 90 mg / ml or more, have a viscosity suitable for injection for subcutaneous delivery, including by self-administration by the patient. In certain embodiments, formulations can be used in combination with an autoinjector having a suitable force of delivery given the viscosity of the formulation.

Provided in the present invention are a new compound that effectively antagonizes integrin α4β7, which is a compound as represented by the following formula (II), or a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug of the compound as represented by the following formula (II).

The present invention is directed to pharmaceutical formulations comprising the anti-α4β7 integrin antibody Vedolizumab. The formulations comprise a specific concentration of sorbitol and shows improved stability properties. Furthermore, the present invention concerns products comprising said formulations and uses thereof for the treatment of various diseases.

In some embodiments, the invention provides a method for identifying an agent beneficial to treat a patient with inflammatory bowel disease comprising: a) determining a status of an intestinal barrier in the patient; and b) categorizing the status as severe dysfunction or moderate dysfunction, wherein a patient categorized as having severe dysfunction is identified as a patient who will benefit from treatment with an agent selected from the group consisting of an anti-TNF agent and / or an anti-IL-12 / 23 agent, and a patient categorized as having moderate dysfunction is identified as a patient who will benefit from treatment with an anti-integrin agent, an anti-janus kinase agent, and / or and a sphingosine-1-phosphate receptor agonist agent.

Provided herein are anti-avb6 integrin engineered polypeptides, fusion proteins thereof with an Fc domain, and pharmaceutically acceptable compositions comprising the same. The anti-avb6 integrin engineered polypeptides of the present technology selectively bind the avb6 integrin with low-nanomolar or picomolar binding activity.

Methods and apparatus for assaying the level of analytes in a sample, related to VLA-4, are disclosed. A method of decreasing the level of an anti-integrin antibody in a subject is described including a) contacting a biological sample from a subject with a detectable capture agent associated with a substrate, wherein the capture agent can bind an anti-integrin antibody in the sample; b) detecting binding of the capture agent with the level of the anti-integrin antibody; and c) treating the subject with plasma exchange until the level of the anti-integrin antibody in the sample reaches a predetermined level.

Provided herein are anti-integrin ανβ6 antibodies, ADCs comprising the anti-integrin ανβ6 antibody and the preparation method thereof, nucleic acids encoding and methods for preparing the anti-integrin ανβ6 antibodies, and the use of the antibodies and ADCs in a variety of diseases.

To provide a novel function blocking antibody to type I collagen receptor integrin alpha 11 beta 1 (α11β1).SOLUTION: Provided are: an anti-integrin alpha 11 beta 1 (α11β1) antibody including (1) a heavy chain including heavy chain complementarity determining region 1 (CDRH1), CDRH2 and CDRH3, and (2) a light chain including light chain complementarity determining region 1 (CDRL1), CDRL2 and CDRL3, where each of the CDRH1 to CDRH3 and CDRL1 to CDRL3 includes an amino acid sequence consisting of a specific sequence; or an antigen-binding fragment thereof; and a method of fabricating and using the antibody. In some embodiments, the anti-α11β1 antibody or the antigen-binding fragment thereof is a monoclonal antibody or an antigen-binding fragment thereof. Also provided is a use of the antibody for treating fibrous disorders and / or cancer.SELECTED DRAWING: None

The present disclosure includes antibodies that specifically bind integrin alpha 11 beta 1 (α11β1), as well as methods of making and using such antibodies.

This invention proposes a new class of compounds that effectively antagonize integrin α4β7, which are compounds represented by formula (II) below, or tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts, or prodrugs of compounds represented by formula (II) below:

The invention provides, inter alia, methods of reducing gastrointestinal immune-related adverse events, such as colitis and diarrhea, in subjects undergoing an immune treatment, such as an immune oncology treatment, such as anti-CTLA4 antibody and anti-PD-1 antibody combination treatment for melanoma. In certain aspects, the methods encompass administering a therapeutically effective amount of a polypeptide that inhibits MAdCAM-integrin binding, such as an anti-α4β7 integrin antibody, such vedolizumab or a related antibody.

The present disclosure includes antibodies that specifically bind integrin alpha 11 beta 1 (α11β1), as well as methods of making and using such antibodies.